VBI Vaccines to study Sci-B-Vac in Phase III programme for hepatitis B

US-based VBI Vaccines is set to evaluate its third-generation hepatitis B vaccine Sci-B-Vac in a global Phase III clinical programme after positive discussions with the US Food and Drug Administration (FDA), Health Canada and the European Medicines A …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news